Read by QxMD icon Read

CyBorD neuropathy

Mohamad Bassam Sonbol, Talal Hilal, Amylou C Dueck, Allison C Rosenthal, Christopher R Conley, Heidi E Kosiorek, Brenda F Ginos, Katherine M Gano, Craig S Nichols, Jose F Leis, Patrick B Johnston, Thomas M Habermann, Donald W Northfelt, Peter Leif Bergsagel, David J Inwards, Thomas E Witzig, Stephen M Ansell, Craig B Reeder
In this phase 2 trial, we sought to evaluate the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) in patients with low-grade NHL. The regimen included rituximab on day 1 with weekly cyclophosphamide, dexamethasone, and bortezomib 1.3 mg/m2 IV in a 28-day cycle. Twenty one patients were enrolled on the study. Median age was 69 years (range 51-80) and 17 (81%) patients had two or more prior treatments. Histologies included FL (n = 8), MCL (n = 8), and LPL/WM (n = 5)...
January 10, 2018: Leukemia & Lymphoma
Arjun Lakshman, Manish Modi, Gaurav Prakash, Pankaj Malhotra, Alka Khadwal, Sanjay Jain, Savita Kumari, Neelam Varma, Subhash Varma
BACKGROUND: Bortezomib-induced peripheral neuropathy (BiPN) is a dose-limiting adverse effect of bortezomib-based therapy for multiple myeloma (MM). The reporting of BiPN is variable because of the use of different neuropathy scales. Most investigators use the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). PATIENTS AND METHODS: We prospectively evaluated the incidence of BiPN in treatment-naive patients with MM receiving weekly cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in 28-day cycles using 3 neuropathy scores: Total Neuropathy Score-reduced (TNSr) and -clinical (TNSc), and NCI CTCAE v4...
August 2017: Clinical Lymphoma, Myeloma & Leukemia
N Areethamsirikul, E Masih-Khan, C-M Chu, V Jimenez-Zepeda, D E Reece, S Trudel, V Kukreti, R Tiedemann, C Chen
Cyclophosphamide, bortezomib and dexamethasone (CyBorD) is a highly active three-drug induction regimen for untreated transplant-eligible multiple myeloma patients. Although CyBorD has been evaluated only in the phase 2 setting in a limited number of patients, its high efficacy and ease of administration have led to its widespread use. Given that clinical trial efficacy can overestimate real-life effectiveness, we reviewed our institutional experience with 109 newly diagnosed patients who were treated with CyBorD in a non-clinical trial setting...
March 2015: Bone Marrow Transplantation
Gunjan Shah, Esha Kaul, Shelly Fallo, Furha Cossor, Hedy Smith, Kellie Sprague, Andreas Klein, Kenneth Miller, Raymond Comenzo
BACKGROUND: Bortezomib is a first-in-class proteasome inhibitor approved by the US Food and Drug Administration for the treatment of all phases of multiple myeloma (MM) and it is also used for the treatment of [corrected] light-chain amyloidosis (AL). The subcutaneous formulation of bortezomib was approved in 2012 based on data from Phase III studies in patients with relapsed MM. OBJECTIVE: This article reports experience with subcutaneous bortezomib in patients with newly diagnosed MM or AL in a tertiary care center...
October 2013: Clinical Therapeutics
Rahma Warsame, Ingrid E Kohut, Angela Dispenzieri
POEMS syndrome is a rare paraneoplastic condition related to myeloma. Because it is rare, there is very little known about treatment options. The use of potentially neurotoxic chemotherapeutic drugs is of concern in a disease whose major manifestation is neuropathy. Herein, we describe an extraordinary response to the combination of cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in a patient with relapsed, life-threatening POEMS syndrome.
June 2012: European Journal of Haematology
Meaghan L Khan, Craig B Reeder, Shaji K Kumar, Marthy Q Lacy, Donna E Reece, Angela Dispenzieri, Morie A Gertz, Phillip Greipp, Suzanne Hayman, Steven Zeldenhurst, David Dingli, John Lust, Stephen Russell, Kristina M Laumann, Joseph R Mikhael, P Leif Bergsagel, Rafael Fonseca, S Vincent Rajkumar, A Keith Stewart
Novel agents are considered standard components of induction therapy for newly diagnosed patients with multiple myeloma. We retrospectively compared the results of three consecutive phase 2 clinical trials; RD (lenalidomide/dexamethasone, n=34), CRD (cyclophosphamide/lenalidomide/dexamethasone, n=53) and CyBorD (cyclophosphamide/bortezomib/dexamethasone, n=63) (N=150). Response rates after four cycles of treatment were: ≥near complete response (nCR), 12% vs. 2% vs. 41%, P<0·0001 and very good partial response or better, 35% vs...
February 2012: British Journal of Haematology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"